This is true as well, but if substantial positive news happens before the IPO, it could very well be that those selling will have to get in at a higher price, unless they are trying to lower the price now by dumping shares to get in at a lower price before the IPO. Right now, either way can be a gamble. It's all about timing, because as it stands, the current trial has had nothing but positive news regarding each patient's dosing, delays aside. The next few months will surely be interesting.